Congratulations to the entire team at Stanford for delivering the world’s first SCINTIX™ therapy treatment. For the first time ever, a tumor has directed its own treatment, ushering in a new era of autonomous radiotherapy. Years in the making, this monumental event expands radiotherapy to metastatic patients with tumors in the lung or bone. SCINTIX therapy is delivered on the RefleXion® X1, the only dual-treatment modality radiotherapy platform capable of treating patients with solid indicated tumors of any stage.
Radiopharmaceutical-directed treatment ushers in a new era of autonomous radiotherapy
HAYWARD, Calif., Aug. 23, 2023 – RefleXion Medical, a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX™ biology-guided radiotherapy on the RefleXion® X1 machine at the Stanford Medicine Cancer Center. SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment.
“We are elated that Stanford Medicine is the first healthcare provider to deliver SCINTIX treatment, marking the first delivery of autonomous radiotherapy,” said Sam Mazin, Ph.D., founder and CTO of RefleXion. “We have been working toward this milestone for over a decade, and on behalf of everyone at RefleXion, I want to thank our early adopter clinical sites, numerous advisors, and our investors for working alongside us to develop and bring to market this new option for patients with all stages of solid tumors.”
